After earning my Master’s degree in Pharmacology, I am currently conducting research at the Laboratory of Toxicological Immunology, within the Department of Innovative Pharmaceutical Sciences at Kyungpook National University. My work focuses on allergic asthma, specifically investigating mast cell mechanisms and utilizing mouse models to study inflammatory responses.

Seoyeong Kim received a B.S. degree in Life Sciences from Yeungnam University and is currently a Master’s student in the Department of Pharmacology, School of Medicine, Kyungpook National University.

Ce Cao is a Ph.D. candidate at the China Academy of Chinese Medical Sciences, currently undertaking a state-sponsored joint training program at the National University of Singapore. His research focuses on cardiovascular pharmacology, specifically cardiac repair and regeneration post-myocardial infarction, and the pharmacological mechanisms of active components in Traditional Chinese Medicine. He has published multiple peer-reviewed papers as a first or co-first author and co-invented several patents related to cardiomyocyte repair therapies. He also serves as a youth committee member of the Network Pharmacology Professional Committee of the Chinese Pharmacological Society.

Aysegul Koc, PhD, is an Assistant Professor in the Department of Medical Pharmacology at Ankara Yıldırım Beyazıt University, Turkey. Her research focuses on airway smooth muscle pharmacology, gaseous transmitters, and receptor-mediated signaling mechanisms in respiratory diseases. She has published in international peer-reviewed journals and presented her work at national and international pharmacology congresses. Her current research explores the interaction between hydrogen sulfide signaling and cannabinoid pathways in airway regulation.

Ms. Sooyoun Lee is a clinical pharmacologist and researcher specializing in pharmacokinetics/pharmacodynamics and model-informed drug development. She is currently involved in clinical trial design and quantitative analysis for early-phase studies, with particular interest in therapeutic drug monitoring, and translational PK modeling. Her recent work focuses on applying advanced modeling approaches to optimize dosing strategies and improve individualization of therapy. She has contributed to multiple clinical research projects and international conference presentations in the field of clinical pharmacology.

Dr. Haihai Liang is a Professor in the Department of Pharmacology at Harbin Medical University, China. He received his PhD in Pharmacology from Harbin Medical University and subsequently joined the faculty, where he leads a research group focused on post‑transcriptional regulation in fibrotic diseases. His laboratory pioneered the concept that RNA‑binding proteins (RBPs) act as conserved master hubs driving fibroblast activation across organs. By integrating CLIP‑seq, transgenic models, and human fibrotic tissues, Dr. Liang’s team dissected the distinct mechanisms of RBPs that converge on pathological matrix production. This work established a new paradigm and proposes targeting RBPs as a unified anti‑fibrotic therapy. Dr. Liang has authored peer‑reviewed papers in journals including European Heart Journal、European Respiratory Journal and Acta Pharmaceutica Sinica B. His research is funded by the National Natural Science Foundation of China.

Dr. Chung-Ping Liao earned his PhD from the Indiana University School of Medicine and completed his postdoctoral fellowship at the University of Texas Southwestern Medical Center. He is currently an Associate Professor in the Graduate Institute of Medical Sciences at Taipei Medical University, Taiwan. Dr. Liao’s research investigates the pathogenic mechanisms of tumors associated with Neurofibromatosis type 1 (NF1). By leveraging sophisticated genetic mouse models, his work has identified the immune microenvironment's critical role in neurofibroma tumorigenesis. His current research seeks to pinpoint key regulators within this microenvironment, with the ultimate goal of developing novel therapeutics for NF1.

Lyndseiy Limosnero joined the Mackay lab located in Bio21 in 2025, working on mast cells, allergic diseases, and potential novel pathway-specific biomarkers for mast cell involvement. Graduating from the University of Melbourne with a Bachelor of Science, majoring in pharmacology, an interest in therapeutics and personalised medicine lead her to pursue further academic study.

Lee-Yuan Lin is a medical student enrolled in the MD–PhD program at Taipei Medical University, Taipei, Taiwan. His research focuses on the molecular mechanisms of pulmonary fibrosis, with particular interest in fibroblast activation, profibrotic signaling pathways, and translational pharmacology. His doctoral work investigates the role of Doublecortin-Like Kinase 1 (DCLK1) in idiopathic pulmonary fibrosis, emphasizing its interaction with Smad3 signaling and contribution to fibrotic progression. In parallel, he has conducted evidence-based medicine research, including systematic reviews and meta-analyses, to contextualize mechanistic findings within clinical and population-level evidence. He also has experience with real-world database analyses.

Yicheng Lin is a second-year Master’s student in Pharmacy (Clinical Pharmacy track) at the School of Pharmacy, Fujian Medical University. He received his Bachelor’s degree in Clinical Pharmacy through a five-year program and is currently pursuing graduate training in clinical pharmacy.

Lu Fang is currently pursuing a doctoral degree at the School of Pharmacy of Ocean University of China. The main research direction is the use of small molecule compounds to treat respiratory diseases, such as asthma and chronic obstructive pulmonary disease. Additionally, she conducts research on skin photoaging.

Wenjuan Ma, PhD, is an Associate Chief Pharmacist at the Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, China. She holds a Bachelor of Pharmacy from Shandong University, Master's degree from Sun Yat-sen University, and doctorate from China Pharmaceutical University, with postdoctoral training at the Affiliated Drum Tower Hospital of Nanjing Medical University. Specializing in nephrology and rheumatology/immunology, Dr. Ma focuses on translational immunopharmacology for autoimmune diseases, particularly systemic lupus erythematosus, with expertise in individualized therapeutics, therapeutic drug monitoring, and the development of novel antibody, peptide, and cell-based therapeutic strategies. Her work has been published in journals including ACS Nano, Advanced Science and Molecular Pharmaceutics. As Principal Investigator, she has led multiple competitive projects including the National Natural Science Foundation of China Young Scientists Fund and major provincial programs in Fujian.

Dr. Wataru Nagata is a medical officer and researcher at the National Defense Medical College, Japan. He is a board-certified specialist in internal medicine and rheumatology. His research covers a broad range of immunological and neuroimmunological mechanisms, focusing on macrophage polarization, autoimmune inflammation, and neuropsychiatric manifestations of rheumatic diseases.

Javier Navarro-Zaragoza is assistant professor and the Head director of the department of Pharmacology in the University of Murcia. Head Director of the ASGRAMUR Chair for research in Severe Asthma.Scientific researcher at the Instituto Murciano de Investigaciones Biosanitarias (IMIB-Arrixaca), since 2010.PI of a Research Project funded by Instituto de Salud Carlos III. Researcher member in 8 national and 4 regional research projects with a total funding of more than 1.6 million euros. PI of 3 Research Contracts art. 60 LOU. Director of 5 Doctoral Theses and currently 5 Doctoral Theses in progress. Author of more than 40 scientific articles, 5 books, 6 book chapters and 4 dissemination articles. Author of 124 communications to national and international conferences.

Dr. Zsófia Onódi is an assistant professor of Department of Pharmacology at Semmelweis University and the head of the Cardioimmunology Research Group. Her research focuses on cardiovascular immunology, concentrating on immune-inflammatory mechanisms in heart failure and other cardiac diseases, including inflammasome signaling, metabolic comorbidities, and pharmacological targeting of inflammatory pathways. In parallel with her research activity, Dr. Onódi is involved in medical education. She teaches pharmacology and clinical pharmacology at undergraduate and graduate levels and has led curriculum development projects introducing flipped-classroom methods and modern assessment strategies into pharmacology teaching. She also contributes to pharmacology textbooks and serves in educational and editorial roles in international pharmacological societies and journals.

Tamkeen Urooj Paracha is a PhD candidate in Cardiovascular and Respiratory Sciences at the University of Calgary. Her research focuses on the molecular mechanisms of airway disease and the pharmacological regulation of airway epithelial biology, with particular emphasis on cyclic AMP (cAMP)/protein kinase A (PKA) signaling. Her work investigates the distinct roles of PKA catalytic subunits and their relevance to β₂-adrenoceptor agonist therapies used in asthma and other obstructive lung diseases. She holds a Doctor of Pharmacy (PharmD) degree from Pakistan and a master’s degree in pharmacology from Naresuan University, Thailand. Her background includes experience in academic teaching, pharmaceutical distribution, and clinical and community healthcare settings. Tamkeen has authored or co-authored nine peer-reviewed publications and has presented her research at international conferences. Her broader interests include translational pharmacology, medication safety, regulatory science, and mentoring early-career researchers, with a long-term goal of strengthening evidence-based healthcare practice.

Ye Jin Jung is a PhD student in pharmaceutical analysis at the College of Pharmacy, Keimyung University, South Korea. Her research focuses on targeted and non-targeted metabolomics and lipidomics using liquid chromatography-mass spectrometry, with an emphasis on extracellular vesicle-associated metabolic profiling in metabolic and cardiovascular diseases.

Ye Jin Jung is a Phd student in pharmaceutical analysis at the College of Pharmacy, Keimyung University, South Korea. Her research focuses on targeted and non-targeted metabolomics and lipidomics using liquid chromatography-mass spectrometry, with an emphasis on extracellular vesicle-associated metabolic profiling in metabolic and cardiovascular diseases.

Eyla Oxborrow is a Bachelor of Medical Science (Honours) graduate at the University of Technology Sydney, with a strong interest in advancing the understanding of chronic lung diseases and identifying new therapeutic targets. Her Honours project investigated the impact of chronic exposure to Sydney air pollution on asthma severity, with an emphasis on the role of dendritic cell responses in disease pathogenesis. Through this work, she aimed to contribute to the development of more effective treatments for asthma and other respiratory diseases.

Merve Kabasakal Ilter, PhD, is a pharmacologist and Asst Prof. at University of Health Sciences Turkey, Medical Pharmacology Department. She completed her PhD in Pharmacology in 2019. Her primary research focus is vascular pharmacology, with expertise in experimental and cell culture–based models. Her research includes studies on the efficacy and safety of novel drug candidates. In addition to her research activities, she is actively involved in the supervision and training of postgraduate students.

Dr. Rimple Jeet Kaur, PhD, is an Associate Professor in the Department of Pharmacology at AIIMS Jodhpur. She serves as the Assistant Dean, Research Section, AIIMS Jodhpur, and the Associate Member Secretary of the Institutional Ethics Committee (IEC), AIIMS Jodhpur, and also contributes as an External Member of the IEC at Dr. S. N. Medical College, Jodhpur. She is the Co-Coordinator of the Medication Safety Committee at AIIMS Jodhpur and actively works toward strengthening patient safety practices. Dr. Kaur is also the Managing Editor of the Journal of Indian Academy of Geriatrics. In the social and public health domain, she serves as the Joint Secretary of the Caregiver’s Asha Society, where she is involved in training trainers to improve medication adherence and medication safety. Her professional contributions span research governance, ethics oversight, medication safety, and capacity building in healthcare.

Consultant Physician MB BS (Syd) FRACP research MD (UNSW) in Pharmacology, Adjunct Associate Professor UNSW Department of Medicine St Vincents Hospital Sydney , Visiting Physician and Cardiologist Mater Hospital as well as private consulting practice. Pharmaceutical industry experience in early drug investigation of a variety of agents with Searle International both locally and overseas. Extensive teaching experience at undergraduate and postgraduate level. Society activities have included membership of numerous RACP committees, the establishment of the Internal Medicine Association of Australia and New Zealand (IMSANZ), foundation member of the Forensic and Clinical Toxicology Association (FACTA) and member of TIAFT. Present research interests include drugs in sport, cannabinoids, forensic pharmacology, statin pharmacology, adverse drug reactions and medical ethics.

Mr. Kuldeep Kumar is working as a Ph.D research scholar at Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala (India) with collaborative research at Department of Pharmacology, AIIMS, New Delhi. His doctoral work focuses on the role of adenosine and cannabinoid receptors in cardioprotective mechanisms. With nearly a decade of academic and research experience, he has served at several reputed institutions of India including Punjabi University, Patiala, Chandigarh University, Mohali, and AIIMS New Delhi. He has authored more than 28 research and review articles in peer-reviewed journals of high impact including Biomedicine and Pharmacotherapy, European Journal of Pharmacology, Molecular Neurobiology etc. and contributed more than 8 book chapters in edited books in the areas of cardiovascular pharmacology, neuropharmacology of Springer-nature, Apple academic press publication house. He is also a reviewer for leading international journals such as Cancer Medicine, Current Cardiology Reviews, Pharmacology research-report and Frontiers in Behavioral Neuroscience. His contributions have been recognized with honors including the Professor O.D. Gulati Award for best work in cardiovascular pharmacology at Annual Conference of the Indian Pharmacological Society (IPSCON-2024) held at AIIMS, New Delhi.

Yarong Liu is an associate professor at Anhui University of Chinese Medicine, a master's supervisor, a new star in Anhui's teaching field, and a young teaching master among the outstanding young talents in Anhui Province. Her main research focuses on the fundamental studies of traditional Chinese medicine in the prevention and treatment of major chronic diseases such as cardiovascular diseases, as well as the pharmacological mechanism research of traditional Chinese medicine in combating atherosclerosis. She has published over 30 scientific research papers. She has received the Fifth National Excellent Doctoral Dissertation Award in Traditional Chinese Medicine and the First Prize for Outstanding Academic Papers in Natural Sciences of Anhui Province.

Master's degree candidate in Guangzhou Medical University

Cam Sinh Lu is a pharmacist and pharmacologist in training, currently undertaking a PhD in Drug Discovery Biology focused on adenosine receptor signalling within the neurovascular unit. Inspired by advances in disease modelling, he integrates molecular pharmacology, computational approaches, and stem cell biology to elucidate receptor mechanisms in neurodegeneration. His long-term goal is to translate these insights into novel cerebroprotective therapeutics that address unmet clinical needs and advance drug discovery.

Vladimir Matchkov is a Professor of Cardiovascular Physiology at Aarhus University, Denmark, where he leads the Neurovascular Coupling Group. He received his PhD from Lomonosov Moscow State University in 1998 and his DMSc from Aarhus University in 2010. His research focuses on cardiovascular function and membrane ion transport, with 124 peer-reviewed publications. He organized and for several years led the Vascular Special Interest Group and currently serves as Secretary-General of the Scandinavian Physiological Society. He also leads the Phenotyping Core Facility at the Department of Biomedicine, with a primary focus on cardiovascular and metabolic disturbances in rodent models. Prof. Matchkov is an active and dedicated teacher of medical physiology.

Prof ‘Makhotso Lekhooa is a researcher in ethnopharmacology, and neuroscience based at the Preclinical Drug Development Platform (PCDDP) of the North-West University. She is an emerging young researcher, with a multi-disciplinary approach to translating traditional medicines ethnobotanical reports into validated scientific data. This work predominately includes evaluating psychoactive plants for anti-depressant potential and neuroinflammation modulation. Additionally validating indigenous plants and/or foods as alternative therapies for co-treatment with conventional drugs to contribute to improved treatment outcomes of Depression, Malaria and Contraception in the global South and contribute to decreasing the incidence of mental health. She is also a Study Director (SD) and Principal Investigator (PI) for client-led preclinical GLP toxicology studies. She has recently, spent a year the Liaoning University of Traditional Chinese Medicines (LNUTCM) in China researching Ginseng and Traditional Chinese Medicines while learning Chinese culture in cross-cultural team. Her international footprint is growing through collaboration with institutions in Germany and South Korea. She serves on the complementary medicine committee of the South African Health Products Regulatory Agency (SAHPRA) with emphasis of ensuring quality compliance of plant-based products. She is passionate about scientific impact and leadership is science to contribute to training the next generation of scientist. She is past Secretary-General and current director of the South African Society of Basic and Clinical Pharmacology (SASBCP) and on the second term tenure of the Young Investigator subcommittee membership of International Union of Basic and Clinical Pharmacology (IUPHAR). She is s Co-founder of the African Chapter of the International Society of the Study of Xenobiotics (ISSX). She is on the board of Pharmacological Research - Natural Products journal and editor for the South African Journal of Botany. She is also a PI of the Tripartite Inter-universities (North West University, University of Limpopo, University of Johannesburg) Research colloquium contributing to capacity building of post-graduate students aligning with the Department of Science, Technology and Innovation decadal plan.

Alex Minopoulos is a final-year PhD candidate at the University of Adelaide. His primary research focus is on functional coronary vasomotor disorders, a non-obstructive form of ischaemic heart disease. His work investigates the effects of novel therapeutics on vascular function and the mechanisms of disease activity.

Mizuna Miyazaki is a researcher in the Department of Pharmacology, Sapporo Medical University, Japan. Her research focuses on the pharmacological mechanisms underlying doxorubicin-induced cardiotoxicity, with particular emphasis on the role of sirtuin activity in cardiac protection and dysfunction. She aims to elucidate molecular pathways involved in cardiac injury and to identify potential therapeutic strategies to prevent or attenuate cardiotoxic effects associated with anticancer agents. Through experimental pharmacological approaches, her work contributes to a better understanding of drug-induced cardiotoxicity and the development of safer pharmacotherapy in oncology.

Giulia Mosini is a clinical pharmacologist at ASST Fatebenefratelli–Sacco. Her professional and scientific activity focuses on pharmacovigilance and clinical trials, with particular expertise in drug safety assessment, risk–benefit evaluation, and regulatory aspects of clinical research. She is involved in AIFA working meetings, contributing to the preparation of pharmacovigilance reports that are subsequently discussed within the Pharmacovigilance Risk Assessment Committee (PRAC). She has experience in the critical analysis of clinical evidence and safety data, supporting decision-making processes in hospital and regulatory settings.

Dr. Siti Safiah binti Mokhtar is a Malaysian academic and researcher in the field of cardiovascular pharmacology and physiology, currently serving as a Senior Lecturer at the School of Medical Sciences, Universiti Sains Malaysia (USM) in Kota Bharu, Kelantan. Her research focuses on vascular and endothelial dysfunction in disease models, including diabetes and obesity, and explores the use of natural products and probiotics as potential therapeutic strategies to improve endothelial and vascular health. She holds a PhD in Pharmacology and has authored numerous scientific publications in areas such as endothelial nitric oxide function, oxidative stress, metabolic disease effects on vascular systems, and gut microbiota modulation in cardiometabolic research.

Prof. Tomoe Y. Nakamura-Nishitani is Professor of Pharmacology at Wakayama Medical University School of Medicine, Japan. Her research focuses on the physiological roles of ion-regulating proteins in the cardiovascular and nervous systems, with particular emphasis on intracellular ion signaling and mitochondrial function. She investigates how dysfunctions of ion channels, transporters, and intracellular Ca²⁺ sensors contribute to cardiac and neurological disorders, integrating cellular electrophysiology, molecular biology, and human iPSC-derived models to advance understanding of disease mechanisms.

Prof. Tomoe Y. Nakamura-Nishitani is Professor of Pharmacology at Wakayama Medical University School of Medicine, Japan. Her research focuses on the physiological roles of ion-regulating proteins in the cardiovascular and nervous systems, with particular emphasis on intracellular ion signaling and mitochondrial function. She investigates how dysfunctions of ion channels, transporters, and intracellular Ca²⁺ sensors contribute to cardiac and neurological disorders, integrating cellular electrophysiology, molecular biology, and human iPSC-derived models to advance understanding of disease mechanisms.

Kenechukwu (Kene) Obikeze is an associate professor of pharmacology and clinical pharmacy, and Deputy director at the School of Pharmacy, University of the Western Cape. He holds a PhD in Pharmacy, and a research career focused on cardiovascular diseases. His primary research interest lies in drug discovery from medicinal plants for the treatment of cardiovascular diseases, with his current focus on identifying and developing cathepsin inhibitors for the prevention and treatment of hypertension, atherosclerosis and myocardial infarction. He is also interested in exploring ion channel blockers or the treatment of CVDs and novel biomarkers to predict cardiorenal disease His work integrates computational modelling, in vitro enzyme assays and cell culture, and in vivo animal models for cardiovascular disease in drug discovery.

Dr. Nik Nor Izah Nik Ibrahim is a researcher in vascular pharmacology with a special interest in endothelial dysfunction and vascular assessment. Her work focuses on non-invasive evaluation of endothelial function using pulse wave analysis, laser Doppler flowmetry, and endothelial microvesicle phenotyping.

Taiwo Omotoso, is a medical doctor, a Consultant Physician/Clinical Pharmacologist in the department of Clinical Pharmacology, University College Hospital (UCH). He is lecturer in the department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria. He has Master of Science (Msc) in Pharmacology and Therapeutic and is a Fellow of West African College of Physicians. He is a public speaker, clinician and a researcher. He attends international medical conferences including American College of Physicians’ premier annual meeting, held in New Orleans, Louisiana, USA April 19-21, 2018 and British Pharmacological Society, PHARMACOLOGY 2024, held in HARROGATE, United Kingdom. He is an active member of Transparency and Reproducibility committee of International Union of Basic and Clinical Pharmacology (IUPHAR).

Saana Pohjavaara graduated in 2021 with an M.Sc. (Pharm) in pharmacology from the University of Helsinki. Fascinated by the potential of in vitro research, she continued working in the Talman group after completing her Master’s thesis. She is currently a doctoral researcher focusing on cardiomyopathy patient-derived hiPSC-cardiomyocytes to deepen the understanding and characterisation of cardiomyopathies using advanced methodologies. In parallel, she investigates the effects of a GATA4-targeting compound in genetic cardiomyopathies.

Juhee Ryu Associate Professor College of Pharmacy, Kyungpook National University Republic of Korea

Michael Sarhene is currently a PhD candidate at the Monash University Institute of Pharmacy and Pharmaceutical Sciences (Drug Discovery Biology group). His research focuses on the characterization of biased agonists of the adenosine A1 receptor, with the aim of elucidating their pharmacological profiles and therapeutic potential for cardiovascular health. He is particularly interested in how ligand bias at G-protein-coupled receptors can be leveraged to improve drug efficacy and safety. Prior to undertaking his doctoral studies, he completed a bachelor’s degree in Molecular Biology and Biotechnology at the University of Cape Coast, Ghana, where he developed a strong foundation in molecular life sciences. He subsequently earned a master’s degree in Pharmacology from Tianjin University of Traditional Chinese Medicine, China, where he further honed his expertise in pharmacological mechanisms and experimental approaches. His interdisciplinary training across diverse research environments underpins his commitment to advancing translational pharmacology and contributes to his ongoing work in biased ligand pharmacodynamics and cardiovascular drug discovery.

Ryushi Sato is a Ph.D. student at the University of Shizuoka's Graduate Program in Pharmaceutical Sciences. Specializing in the electrophysiology of iPSC-derived cardiomyocytes, he analyzes action potentials and ionic currents (If, IK1, ICaL) using manual patch-clamp methods. His current research investigates the maturation of cardiomyocytes promoted by electrical pacing.

Dr. Elif Guzel is a research assistant at Istanbul Medipol University School of Medicine, Department of Medical Pharmacology, Istanbul, Türkiye. She received her bachelor’s degree from the School of Pharmacy at Altınbaş University in 2019. Then, she began her master’s studies at the University of East London, School of Health, Sport and Bioscience in London, UK, and graduated in 2021. In the same year, she began her doctoral studies in medical pharmacology and graduated in 2025. Her primary field of interest is neuropharmacology, with a particular focus on Parkinson’s disease, circadian rhythm, and TRP channels. She is still conducting scientific research projects supported by higher education institutions, on Parkinson’s disease, circadian rhythm, and TRP channels. She also teaches pharmacology and clinical pharmacology lectures at the Istanbul Medipol University, School of Medicine and School of Dentistry.

An assistant professor at the Department of Pharmacology and Toxicology at the College of Medicine in Kuwait University. I have more than ten years of experience in research and more than 30 research articles in internationally recognized journals. I graduated from Kuwait University with a B.Sc. in Biochemistry and Molecular Biology. I pursued my graduate studies in Canada. I obtained an M.Sc. degree in Pharmacology from Dalhousie University and a Ph.D. degree in Physiology and Pharmacology from the University of Western Ontario. My main research interest is the group of G Protein-Coupled Receptors (GPCRs) which represents the target for more than 40% of drugs currently on the market. I believe that understanding the signaling and trafficking of GPCRs is critical for improving drug discovery. My current receptor of interest in the Melanocortin 4 receptor (MC4R) which plays an important role in regulating appetite and energy homeostasis.

Zahra Hashemi is a seasoned pharmacist and healthcare professional with over three decades of diverse experience spanning community and hospital pharmacy, clinical research, regulatory affairs, pharmaceutical imports, and academic administration. Her core expertise includes prescription evaluation, patient counseling, pharmacovigilance, drug dispensing, compounding, inventory management, and ensuring safe storage of medicines. She has held senior leadership and technical roles in India, Iran, the UAE, and Australia, including Deputy Director at the Centre for Advanced Study in Pharmacology, Ibn Sina Academy, Aligarh, and Technical Manager in multiple pharmaceutical organizations. She has actively contributed as a Research Coordinator in multicentric Phase II and Phase III clinical trials in oncology, with hands-on experience in patient consent, CRF management, SAE reporting, and drug accountability. An Accredited Mental Health First Aider (Australia), she has also been involved in post-marketing surveillance, regulatory liaison with Ministries of Health, and the establishment of traditional medicine systems. Participation in hundreds of national and international seminars and conferences reflects a strong commitment to continuous professional development and advancement of healthcare practice.

Hideki Hayashi is an Associate Professor at Tokyo University of Pharmacy and Life Sciences. His research focuses on neuroscience, with a particular interest in the neuroprotection of optic nerve cells.

Miss He is a PhD student at The Chinese University of Hong Kong. Her research focues on the emetic effects of GLP-1 receptor agonists in animal models with different sensitivities to motion. She has conducted meta-analyses on 5-HT3 receptor antagonists for cisplatin-induced emesis and aims to incorporate similar evidence-based approaches into her doctoral research.

Zsuzsanna Helyes graduated as a medical doctor (1995), obtained PhD (1998), specialized at clinical laboratory diagnostics (2001) and clinical pharmacology (2004). She is a full professor at the Department of Pharmacology and Pharmacotherapy of the University of Pecs Medical School, member of the Hungarian Academy of Sciences and Academia Europea. She is extensively involved in teaching and training; 26 PhDs were defended under her supervision. She received several decorations including “Master Supervisor” Golden Medallion, "Pro Cura Ingeni" Award, Knight of Cross from the Order of Merit of the Hungarian Republic and “Denis Gabor”. Her research focuses on neuropharmacology and the sensory system, the role of capsaicin-sensitive peptidergic afferents and neuro-vascular-immune interactions in inflammation and pain, as well as related psychological co-morbidities such as anxiety and depression. She aims to identify novel targets for analgesic, anti-inflammatory and anti-depressant drugs. She published 290 papers with 1230 impact factor and 12311 citations, her h-index is 61, she owns 12 patents. One of her novel firs-in-class analgesic drug candidates has successfully completed Phase IA clinical trials. She is intensively promoting academy-industry cooperations. She is a senior editor of British Journal of Pharmacology, editor of Scientific Reports and Frontiers in Pharmacology, president of the Hungarian Society of Experimental and Clinical Pharmacology and steering committee member of the Hungarian Pain Society and Physiology Society.

Atsuya Ikeda is a graduate student at Okayama University. He is majoring at neurodegenerative diseases, including Alzheimer’s disease. His aim is to elucidate the role of lipid transport abnormalities in disease progression and to explore potential therapeutic approaches.

Prof. Baiba Jansone is Head of the Department of Neuromedicine and Neuroscience at the Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia. Previously, she led the Department of Pharmacology at the University of Latvia (2017–2024). She has served as principal investigator on multiple ERA-NET NEURON and other research projects. Her research focuses on neuroinflammation, dysfunctions of key neurotransmitter systems (GABAergic, cholinergic, and glutamatergic), and pharmacological approaches to brain disorders, with a particular emphasis on neurodegenerative diseases.

Tzu-Jen Kao is a Professor in the Department of Medical Science and Technology at Taipei Medical University, Taiwan, and serves as Director of the university’s Bilingual Education Promotion Center. His research focuses on the molecular and neuropharmacological mechanisms that regulate neuronal development, axon growth, and regeneration, with particular interest in motor neuron biology. Using integrated in vitro and in vivo models, his work investigates how neuroactive compounds, including neurosteroids and other endogenous modulators, influence neuronal structure and function through defined intracellular signaling pathways. His laboratory combines molecular genetics, pharmacological manipulation, and quantitative imaging approaches to identify critical mediators of neuronal growth with translational potential. In addition to his research activities, Professor Kao is actively involved in interdisciplinary education and international collaboration in neuroscience and pharmacology. His work aims to bridge basic mechanistic discoveries with translational strategies for neural repair and neuropharmacological intervention.

Dr. Kübra Karadağ Görgülü is a specialist in Medical Pharmacology and a lecturer at the Hamidiye Faculty of Medicine, University of Health Sciences in Istanbul. She completed her medical education at Atatürk University, followed by her Medical Pharmacology residency at Hacettepe University (2020–2024). Her research focuses on neuropharmacology, behavioral neuroscience, and experimental models of neurodevelopmental and psychiatric disorders. She has contributed to various peer-reviewed publications in the fields of neuropsychopharmacology and anatomy, and has served as a researcher in several university-funded projects on Sigma-1 receptor modulation, valproic acid-induced autism models, and experimental behavioral sensitization. Dr. Karadağ Görgülü has participated in national neuroscience and pharmacology congresses with her work and as an attendee. She has completed certified trainings in cell culture, protein analysis techniques, good clinical practice, laboratory animal use, and biostatistics.

Dr Reeta is Professor, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi. Dr Reeta is a Fellow of National Academy of Medical Sciences (2022) and Fellow of Indian Pharmacological Society (2023). Dr Reeta is a recipient of awards including Dr Vinod Kumar Bhargava Award of the National Academy of Medical Sciences (2017), AIIMS Research Excellence Award for outstanding publication (2024 and 2016), Shakuntala Amir Chand Award of ICMR (2013), CL Malhotra Prize of the Association of Physiologists & Pharmacologists of India (2006), Best Oral Paper Presented, 3rd North Zone Conference of Indian Pharmacological Society, New Delhi, (2005). She has been a gold medallist and university topper in her MBBS. She is the Associate Editor, Frontiers in Pharmacology (October 2023 - till date) and was the Associate Editor of the Indian Journal of Physiology & Pharmacology (2009-2012). She has 73 published articles in national and international journals of repute, 6 books/chapters in books and more than 128 published abstracts presented in various national and international conferences. She has handled 27 research projects as principal/ co- investigator. Dr Reeta has organized more than 25 workshops/symposia as Organizing secretary/joint organizing secretary/organizing committee member. Her areas of interest are neuropharmacology and clinical pharmacology.

Dr. Seong Yun Kim is working as a Professor of Department of Pharmacology, College of Medicine at The Catholic University of Korea. Professor Kim received his MD and PhD from The Catholic Medical College, respectively. With over 40 years of experience in the neuropharmacology, he has authored over 100 peer-reviewed papers. His research interests include neurogenesis in the adult mammalian brain and the pathophysiology of cerebral ischemia and temporal lobe epilepsy.

Mojca Kržan, MD, PHD Curriculum vitae EDUCATION: Graduated in 1886 at Faculty of Medicine, University of Ljubljana. In 1990 defended M.Sc. thesis and in 1995 Ph.D. thesis in pharmacology of cardiac histamine receptors. From September 1996 till 1998 I spent as a postdoctoral fellow at NINDS - NIH in Bethesda, Maryland, USA. RESEARCH INTERESTS: basic pharmacology and neuropharmacology. EMPLOYMENT: from 1986 till 1994 I was a research fellow; later teaching assistant, from 2003 till present a professor of pharmacology at the Department of Pharmacology, Faculty of Medicine, University of Ljubljana. I served two terms as Head of Department. MEMBERSHIPS: I am member of Slovenian Pharmacological Society and Federation of European Pharmacological Societies, where I served as president from 2018-22.

Dr. Mei-Chuan (Holden) Ko is a behavioral neuropharmacologist whose work focuses on pain, addiction, and the development of safer, non-addictive therapeutics using translational non-human primate models. He earned his PhD and completed postdoctoral training at the University of Michigan and is currently appointed as a tenured Professor in the Department of Psychiatry at the University of Pittsburgh School of Medicine. Dr. Ko has published over 100 peer-reviewed articles with the h-index of 50. His research has revealed that nociceptin/orphanin FQ peptide receptor agonists provide effective, non-addictive analgesia and discovered a primate-specific synergy between nociceptin and opioid receptor activation that led to the development of first-in-class dual NOP/MOP agonists now advancing toward IND-enabling studies and clinical trials. His work exemplifies impactful translational science, innovation, and productive collaboration aimed at addressing urgent public health needs.

Dr. Ming Tatt Lee was born and raised in Penang, Malaysia. He obtained his B.Sc. (Biomedical Science) and Ph.D. (Physiology) degrees from Universiti Putra Malaysia. DHe is currently holding the Director position of the Office of Postgraduate Studies (OPS), in which he is tasked to oversee all the postgraduate programmes at UCSI University. He received multiple awards/grants from national and international associations including the Malaysian Society for Neuroscience (MSN), International Brain Research Organization (IBRO), Federation of Asian Oceanic Neuroscience Society (FAONS), Federation of European Neuroscience Societies (FENS), Malaysian Toray Science Foundation (MTSF), etc. Dr Lee has been actively publishing in high-impact journals in the field of neuropharmacology. His research interests include the neurobiology of pain, neuropsychiatric disorders, and movement disorders in various preclinical models. Dr Lee is a Professional Technologist under Malaysian Board of Technologists (MBOT) and a registered Medical Laboratory Scientist under the Malaysian Allied Health Professions Council (MAHPC).

Kirsten is a registered pharmacist and a PhD Candidate at the Centre for Medicine Use & Safety within the Monash Institute of Pharmaceutical Sciences. She holds a Master of Research in Pharmacy and has led various pharmacy practice projects, including those for the International Pharmaceutical Federation. Kirsten's PhD topic is "Establishing Evidence for Clinical Practice Guidelines on Ketamine and Esketamine for Major Depressive Disorder", and she is eager to contribute further in this field.

Mrs. Juan Li is a professor holding a doctoral degree in the field of neuropharmacology. Her research program focuses on the molecular mechanisms underlying neuroinflammation associated with Alzheimer’s disease, as well as identification and validation of novel intervention targets for this neurodegenerative disorder. She conducts mechanistic and translational studies to delineate neuroinflammatory regulatory pathways, aiming to develop potential therapeutic strategies for Alzheimer’s disease.

Dr. Mahajan is an Assistant Professor and Officiating Head in the Department of Pharmacology at AIIMS Vijaypur, Jammu. Her academic and research interests include pharmacovigilance and materiovigilance, rational use of medicines, prescription analysis, antimicrobial stewardship, drug regulatory affairs, and clinical trials. She is committed to advancing safe and rational pharmacotherapy through academic teaching, institutional research, and policy development. Dr. Mahajan has experience across clinical, academic, and administrative domains, with active involvement in ethics committee work, research coordination, and curriculum development. She has contributed to several institutional initiatives, including the development of digital prescription analytics systems and pharmacovigilance monitoring programs. Through her research, teaching, and institutional leadership, she continues to support improvements in pharmacology education, patient safety, and clinical outcomes.

April 2022 – Present: Associate Professor, Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan April 2022 – Present: Associate Professor, Food and Animal Systemics, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan May 2013 – Present: Associate Professor, Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan October 2005 – May 2013: Assistant Professor, Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan April 2004 – September 2005: Research Fellow, Yale University School of Medicine, New Haven, CT, USA April 2002 – March 2005: Research Fellow (DC/PD), Japan Society for the Promotion of Science (JSPS), Japan

Dr. Rajendra Nath is a Professor of Pharmacology and Therapeutics at King George’s Medical University (KGMU), Lucknow, India, with over 25 years of teaching and research experience. He earned his MBBS from King George’s Medical College, Lucknow University, in 1985 and completed his MD in Pharmacology and Therapeutics in 1989, both on first attempt. Dr. Nath has served KGMU in various academic roles, including Demonstrator, CSIR Research Associate, Lecturer, Associate Professor, and Professor. He has extensive teaching experience across undergraduate and postgraduate programs, including MBBS, BDS, nursing, paramedical, diploma pharmacy, MD, MPhil, and PhD courses. He has supervised and co-supervised numerous MD, MPhil, and PhD theses and has served as an internal and external examiner for professional examinations. His primary research interests include neurocardiovascular pharmacology, drug development, clinical pharmacology, and basic and ethnopharmacology. Dr. Nath is a co-author of the textbook MCQs in Pharmacology and has published more than 160 research papers in national and international peer-reviewed journals. His recent research focuses on neurodegenerative disorders, neuroinflammation, Parkinson’s disease models, learning and memory modulation, metabolic disorders, and emerging applications of artificial intelligence in drug development. Dr. Nath is an active member of several professional organisations, including the International Society of Heart Research (Indian Section), American Society for Pharmacology and Experimental Therapeutics (ASPET), Indian Society of Hypertension, Indian Medical Association, and Uttar Pradesh Diabetes Association. His academic and research contributions have been recognised with numerous honours, including the Bharat Jyoti Award, Indira Gandhi Shiromani Award, Dr. Abdul Kalam Azad Award, and election as a Member of the National Academy of Medical Sciences.

Dr. Javier Navarro-Zaragoza holds a PhD in Pharmacy and a degree in Human Nutrition and Dietetics. He is an Associate Professor in the Department of Pharmacology at the Faculty of Pharmacy, University of Murcia, and a researcher at the Biomedical Research Institute of Murcia Pascual Parrilla (IMIB).

Sheikh Sana Nazir is a passionate researcher with three years of experience in computational, in-vitro, and in-vivo experiments. He is currently pursuing a PhD in Pharmacology at Jamia Hamdard, New Delhi, India. He has experience in handling and working with SH-SY5Y neuroblastoma cell lines, performing biophysical assays, conducting various cell-based assays, and working with different animal models, specifically developing Alzheimer-related animal models using stereotaxy. He has qualified the Graduate Pharmacy Aptitude Test (GPAT) and has published in international journals.

Ha Thi Viet Nguyen is affiliated with the Discipline of Pharmacology & Therapeutics at the University of Galway. She is a pharmacist from Vietnam and holds a master’s degree in Pharmacology, Toxicology, and Physiology, with a focus on preclinical research, from Paris Descartes University. She is currently a third-year PhD student in Pharmacology at the University of Galway. Her primary research interest is neuropharmacology, with a particular emphasis on antipsychotic drug development for schizophrenia. Her doctoral research involves conducting systematic reviews and meta-analyses of pharmacological, genetic, and neurodevelopmental models of schizophrenia to assess their predictive and translational validity in preclinical antipsychotic research.

Dr. Yousra Nomeir is an Assistant Professor in the Department of Pharmacology and Clinical Pharmacy at College of Medicine & Health Sciences, Sultan Qaboos University, Oman, specializing in Clinical Pharmacology and Toxicology. She holds a MSc and PhD in Pharmacology and Toxicology from Stiftung Tierärztliche Hochschule Hannover, Germany, and has extensive interests in neuroscience, cardiovascular pharmacology, and herbal medicine. Her academic and research work primarily focuses on neuroscience, clinical pharmacokinetics, therapeutic drug monitoring, and drug utilization.

Yutaro Obara, Ph.D., is a Professor of the Department of Pharmacology at Yamagata University School of Medicine, Japan. After receiving his B.S. in Pharmaceutical Sciences from Tohoku University, Japan in 1997, Obara earned his Ph.D. in Pharmaceutical Sciences from Tohoku University in 2002. He worked as a JSPS Research Fellowship for Young Scientists (1999-2005). He was a postdoctoral fellow in Vollum Institute, Oregon health Sciences University (2002-2003). He spent 7 years as an assistant professor at Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University (2005-2012). Obara joined Yamagata University as an associate professor in 2012 and promoted to professor in 2021. His contributions have been honored with Academic Encouragement Award by Japanese Pharmacological Society in 2013.

Eric Okrah is a final year PhD candidate in Annesley’s Lab at La Trobe University, Australia. I have a background in Pharmaceutical Sciences, focused on drug discovery, with a wealth of research experience, solid laboratory skills, and techniques in research pharmacology. My PhD research is focused on investigating the therapeutic potential of cannabis-derived compounds for the treatment of Parkinson’s disease. I aspire to significantly contribute to developing novel therapeutics for the treatment of neurological and neuropsychological disorders by alleviating multiple pathophysiological processes and targeting specific receptors and ion channels to improve drug target and design. I aim at utilizing drug discovery to uncover new biological pathways involved in disease progression, with a strong interest in translating natural product research into clinical solutions.

Eric Okrah is a final year PhD candidate in Annesley’s Lab at La Trobe University, Australia. I have a background in Pharmaceutical Sciences, focused on drug discovery, with a wealth of research experience, solid laboratory skills, and techniques in research pharmacology. My PhD research is focused on investigating the therapeutic potential of cannabis-derived compounds for the treatment of Parkinson’s disease. I aspire to significantly contribute to developing novel therapeutics for the treatment of neurological and neuropsychological disorders by alleviating multiple pathophysiological processes and targeting specific receptors and ion channels to improve drug target and design. I aim at utilizing drug discovery to uncover new biological pathways involved in disease progression, with a strong interest in translating natural product research into clinical solutions.

Dr. Pal Graduated and Post graduated from University of Delhi and done PhD in 2007, from V. P. Chest Institute, Faculty of Medicine, University of Delhi. Awarded postdoctoral fellowship in 2008, by University of Texas, MD Anderson Cancer Center, Houston Texas, USA for work on signal transduction pathway mediated through NF-kB by immune stimuli. Dr. Pal is currently working as Professor in Department of Pharmacology and Therapeutics, King George’s Medical University, UP, Lucknow. His area of research is neurodegenerative and inflammatory disorders and currently, working on STATs, NF-kB, RIP kinase, and autophagy signal transduction pathways and their modulation by pharmacological agents in psycho-neuro-immunological and neurodegenerative disorders with the help of intramural and extramural research grants. Dr. Rishi Pal supervised 02 PhD and 12 MD (Pharmacology) theses and serving as editorial board member of scientific journals namely International Immunopharmacology and academic editor of International Journal of Rheumatic Diseases. Dr. Pal has been awarded Excellence in research award by Honorable vice chancellor of KGMU for his high impact research. He is member of more than 10 scientific research societies including Royal Society of Chemistry, UK and National Academy of Medical Science (India). Dr. Pal published more than 65 research papers, 08 book chapters and a book with H-index of 11 with more than 780 citations to his credit.

Dr. Pal Graduated and Post graduated from University of Delhi and done PhD in 2007, from V. P. Chest Institute, Faculty of Medicine, University of Delhi. Awarded postdoctoral fellowship in 2008, by University of Texas, MD Anderson Cancer Center, Houston Texas, USA for work on signal transduction pathway mediated through NF-kB by immune stimuli. Dr. Pal is currently working as Professor in Department of Pharmacology and Therapeutics, King George’s Medical University, UP, Lucknow. His area of research is neurodegenerative and inflammatory disorders and currently, working on STATs, NF-kB, RIP kinase, and autophagy signal transduction pathways and their modulation by pharmacological agents in psycho-neuro-immunological and neurodegenerative disorders with the help of intramural and extramural research grants. Dr. Rishi Pal supervised 02 PhD and 12 MD (Pharmacology) theses and serving as editorial board member of scientific journals namely International Immunopharmacology and academic editor of International Journal of Rheumatic Diseases. Dr. Pal has been awarded Excellence in research award by Honorable vice chancellor of KGMU for his high impact research. He is member of more than 10 scientific research societies including Royal Society of Chemistry, UK and National Academy of Medical Science (India). Dr. Pal published more than 65 research papers, 08 book chapters and a book with H-index of 11 with more than 780 citations to his credit.

Bojana B. Petrović, MPharm, PhD, began her career in the healthcare sector (2005–2010) and later worked at the pharmaceutical company Galenika a.d. (2010–2012) in the Department of Liquid and Semi-Solid Products. Since 2013, she has been employed at the Sanitary Medical School of Applied Sciences in Belgrade, where she is a Professor of Applied Sciences in the fields of pharmacy and pharmacology. She has supervised around 60 graduate theses. From 2016 to 2020, she reviewed medical study programs for the recognition of foreign educational documents at the ENIC–NARIC Centre of Serbia. In 2024, she was appointed Professional Supervisor for external quality control in healthcare institutions in the field of pharmacy, by the Ministry of Health. She also mentored in the Imagine IF! Accelerator (University of Cambridge, 2019–2020). Her research focuses on pharmacovigilance, cancer therapies, neuropharmacology, and the history of pharmacy, with numerous publications, monographs, and textbooks.

Dr. Li Feng is a postdoctoral researcher at Xinqiao Hospital, Army Medical University. Her research focuses on the molecular mechanisms underlying tumorigenesis and progression, with recent studies revealing the role of NR3C2 in colorectal cancer and identifying a novel NR3C2–SIRT1 signaling axis. She looks forward to sharing her work and engaging in scientific exchange at WCP2026.

A/Professor Lu Liu is a pharmacologist whose research focuses on the mechanisms and treatment of gastrointestinal and urinary bladder diseases. She has over 20 years of experience investigating disorders including inflammatory bowel disease, irritable bowel syndrome, constipation, diverticular disease, overactive bladder, urinary tract infections, and bladder urothelium dysfunction. She completed her PhD in Pharmacology at Monash University in 1998 and was awarded the Mollie Holman Medal for Thesis Excellence. She subsequently held NHMRC-funded research positions at UNSW and has received national and international recognition for her work. Since 2006, she has been an academic in the School of Biomedical Sciences at UNSW, combining research and teaching. As Chief or Sole Investigator, she has secured more than $3 million in competitive funding, including four NHMRC project grants, and has published extensively in gastrointestinal and bladder research.

LIU Yuen Hang Julia earned a Bachelor of Molecular Biomedical Sciences from the Hong Kong University of Science and Technology in 2013 and a PhD in Biomedical Sciences from the Chinese University of Hong Kong in 2017. Her research interests include anti-aging and gut electrophysiology, with over 20 publications in these fields. In 2020, she began commercializing her research in gut electrophysiology and became the CEO of Gut Rhythm in 2022, a Hong Kong start-up focused on developing a gut electrophysiology drug testing platform. The company also manages the online Gastrointestinal Pacemaker Activity Drug Database (GIPADD), an open resource with over 14,000 datasets.

Prof. Jianfei Long is an Associate Researcher and MD in Clinical Pharmacy at Fudan University, serving as a Master’s supervisor. She is a clinical pharmacist at Huashan Hospital and a committee member of the Chinese Geriatrics Society. Prof. Long leads multiple projects funded by National Natural Science Foundation of China, has published over ten first-author SCI papers (Impact Factor up to 26.8), and received awards including the Chinese Pharmaceutical Association Outstanding Case Award. His research focuses on gut microbiota in chronic disease and vestibular schwannoma organoid models for drug screening and mechanistic studies.

Professor Saito graduated from the Faculty of Medicine at Tottori University, Japan, in 1991. He completed his residency at Tottori University Hospital before undertaking postdoctoral research in the Section of Urology at Yale University School of Medicine (1993–1996). He earned his PhD in Medicine from Tottori University in 2000. Prof Saito went on to serve as Assistant Professor and later Associate Professor in the Department of Urology and the Division of Molecular Pharmacology at Tottori University. Since 2013, he has been the Chairman and Professor of the Department of Pharmacology at Kochi Medical School, Kochi University, Japan.

Dr. Mikako Nagashima is an Assistant Professor in the Department of Pharmacology, Faculty of Medicine, Yamagata University, Japan. She graduated from Yamagata University School of Medicine in 2017 and completed her postgraduate clinical training at Nihonkai General Hospital in 2019. She then worked in the Department of Obstetrics and Gynecology at Yamagata University Hospital until 2022. In 2023, she was appointed Assistant Professor in the Department of Pharmacology at Yamagata University. She earned her Ph.D. in Medical Science from the Graduate School of Medicine, Yamagata University in 2025. Her research focuses on the molecular basis of ovarian cancer progression, with particular interest in Midnolin and tumor cell signaling.

Her research focuses on the mechanisms regulating gastrointestinal motility, particularly how mechanical stretch regulates smooth muscle contractions and how this contributes to gastrointestinal motility. Currently, she investigates the role of Piezo1, a mechanosensitive cation channel, in the regulation of gastrointestinal motility in response to mechanical stimuli, using cell-specific Piezo1 knockout mouse models. She has presented her work at several national and international conferences. In 2023, she received the Best Research Award at the 10th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2023) for her research contributions. She pursues basic research in gastrointestinal physiology to provide fundamental insights that may inform future advances in gastroenterology.

Martha Ofokansi is a Lecturer in the Department of Pharmacology and Toxicology at the University of Nigeria. She holds a PhD in Pharmacology with a specialization in natural product pharmacology. Her research focuses on the pharmacological and toxicological evaluation of medicinal plants, with particular emphasis on safety profiling, efficacy and therapeutic potential. She employs experimental models alongside analytical techniques such as GC–MS and HPLC in the characterization of bioactive compounds. Her work contributes to advancing evidence-based drug discovery from natural source.

Associate Professor at Dept Pharmacy Practice, Fac of Pharmacy, Univ Airlangga, Surabaya, Indonesia. Chair of Biomedical Pharmacy Research Group at Fac of Pharmacy, Univ Airlangga, Surabaya, Indonesia Majoring on basic Gastro-intestinal Pharmacology and Neuropharmacology

Prof. Rudd is a pharmacologist known for his significant contributions to chemotherapy-induced emesis research. In the late 1980s, he worked at Glaxo Group Research, studying the 5-HT3 receptor antagonist, ondansetron, and mapping 5-HT3 receptor distribution in human and ferret brainstems. He discovered that NK1 tachykinin antagonists could prevent acute and delayed emesis caused by cisplatin, leading to their adoption as a cornerstone treatment. Recently, he collaborated with Helsinn Healthcare on developing second-generation 5-HT3 and NK1 receptor antagonists. With experience in nearly 30 pharmaceutical companies, he founded Gut Rhythm R&D (HK) Ltd., which houses the innovative ‘Gastro-Intestinal Pacemaker Activity Drug Database’ (GIPADD). He is currently working on GLP-1 and peptide mechanisms associated with nausea and emesis. His laboratory specializes in the use of radiotelemetry to access information on gastric myoelectric activity. He is the Honorary Secretary of the Hong Kong Pharmacology Society.

Dr Sellers has forged a distinguished academic career combining research and teaching at leading universities and hospitals in the United Kingdom and Australia. Focussing her research interests on the physiological and pharmacological function of the urinary bladder, she collaborates with clinical, academic and industry partners to better understand the lower urinary tract and the mechanisms underlying disorders such as overactive bladder function, to aid the future development of novel treatments. Complementing her research portfolio, Dr Sellers has taught at the undergraduate and postgraduate level at Sheffield Hallam University, the University of Sheffield and the University of Manchester prior to joining Bond University's Faculty of Health Sciences and Medicine in 2009, where she is a member of the Centre for Urology Research.

Meei-Ling Sheu is a Lifetime Distinguished Professor and Director of the Institute of Biomedical Sciences, College of Life Sciences, National Chung Hsing University, Taichung, Taiwan. In recent years, she has also focused on innovation, research and development, and management in the biotechnology industry, serving as a unit director. With over 20 years of experience in basic and translational research on tumor metastasis and vascular medicine, Professor Sheu has published more than 100 peer-reviewed articles and led several national-level research grants. Her current work centers on integrating advanced small-molecule development and imaging diagnostics into potential therapeutic pathways. Her research aligns closely with the theme of the 20th World Congress of Basic and Clinical Pharmacology (WCP 2026) — “Advancing Pharmacology Globally Through Collaboration and Discovery.” She will address the interface between specific molecular targets and tumor-associated macrophages in cancer metastasis. Outside of her professional role, Professor Sheu enjoys mountain climbing and swimming. For more information, please visit https://biomed.nchu.edu.tw/node/352.

Dr. Yong Jiang currently acts as the full professor and the dean of Department of Natural Medicines Chemistry, School of Pharmaceutical Sciences, Peking University. Her major research interests focus on the studies of the discovery of effective components and its mechanisms of traditional Chinese medicines.

Professional Experience April 1989 – November 1992: Research Scientist, Department of Pharmacology, Central Research Laboratories, Banyu Pharmaceutical Co., Ltd. December 1992 – July 1999: Assistant Professor, Laboratory of Veterinary Pharmacology, Faculty of Agriculture, Gifu University April 1998 – April 1999: Overseas Research Fellow supported by Ministry of Education, Culture, Sports, Science and Technology, University of London, United Kingdom August 1999 – March 2004: Associate Professor, Faculty of Agriculture, Gifu University April 2004 – May 2008: Associate Professor, Faculty of Applied Biological Sciences, Gifu University April 2007 – May 2008: Concurrent Associate Professor, United Graduate School of Veterinary Sciences, Gifu University June 2008 – Present: Professor, Faculty of Applied Biological Sciences, Gifu University June 2008 – Present: Concurrent Professor, United Graduate School of Veterinary Sciences, Gifu University April 2019 – Present: Concurrent Professor, Joint Graduate School of Veterinary Sciences, Gifu University

Professional Experience April 1989 – November 1992: Research Scientist, Department of Pharmacology, Central Research Laboratories, Banyu Pharmaceutical Co., Ltd. December 1992 – July 1999: Assistant Professor, Laboratory of Veterinary Pharmacology, Faculty of Agriculture, Gifu University April 1998 – April 1999: Overseas Research Fellow supported by Ministry of Education, Culture, Sports, Science and Technology, University of London, United Kingdom August 1999 – March 2004: Associate Professor, Faculty of Agriculture, Gifu University April 2004 – May 2008: Associate Professor, Faculty of Applied Biological Sciences, Gifu University April 2007 – May 2008: Concurrent Associate Professor, United Graduate School of Veterinary Sciences, Gifu University June 2008 – Present: Professor, Faculty of Applied Biological Sciences, Gifu University June 2008 – Present: Concurrent Professor, United Graduate School of Veterinary Sciences, Gifu University April 2019 – Present: Concurrent Professor, Joint Graduate School of Veterinary Sciences, Gifu University

Yangli Huang (born in August 2000) is a Ph.D. candidate at Beijing University of Chinese Medicine. Her research primarily focuses on the therapeutic effects and mechanisms of Carthamus tinctorius (safflower) in cardiovascular diseases.

My name is Shuto Itokazu. I am a pharmacist and a Ph.D. student in the Department of Clinical Pharmacology and Therapeutics at the Graduate School of Medicine, Tokushima University, in Tokushima, Japan. I received a bachelor’s degree in pharmacy. PUBILICATIONS 1. Kaito Tsujinaka Syuto Itokazu et al. Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection. Biomed Pharmacother. 2023 Nov:167:115504. 2. Koji Miyata, Syuto Itokazu et al. Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments. Biomed Pharmacother. 2024 Oct:179:117418. 3. Koji Miyata, Shuto Itokazu et al. Pharmacovigilance Study for the Identification of Mogamulizumab-Induced Immune-Related Adverse Events Using a Real-World Database. The Oncologist 2025 Jul 4;30(7)

Alex Minopoulos is a final-year PhD candidate at the University of Adelaide. His primary research focus is Functional Coronary Vasomotor Disorders, a non-obstructive form of ischaemic heart disease. Alex's work includes investigating the effects of novel therapeutics on vascular function as well as looking into potential biomarkers for disease activity.

Fourth-year pharmacology resident with a particular academic interest in pharmacogenetics, which constitutes the focus of my MD thesis.

Fourth-year pharmacology resident with a particular academic interest in pharmacogenetics, which constitutes the focus of my MD thesis.

Maree Smith AC is a full-time researcher and Director of the Centre for Integrated Preclinical Drug Development (CIPDD) in the School of Biomedical Sciences at The University of Queensland (UQ). The mission of the CIPDD is to assist industry and academic researchers to progress their drug discovery IP towards commercialisation into products for improving human health. Internationally, she is a leading researcher in biomedical discovery/translation with particular expertise in the novel pain therapeutics field. Although her focus is on IP-sensitive research, she has maintained an excellent publication output, with >200 publications. She has advised/co-advised 33 PhD students and >50 Research Masters/ Honours students to completion, as well as mentored numerous EMCRs over the past decades. She is currently advising 3 PhD students and an Honours student as well as co-advising 3 PhD students.

Hero Maera is an undergraduate student at the University of California, Davis, double majoring in Psychology (Quantitative) and Cognitive Science (Neuroscience). Their interests center around the mechanisms and treatments of neuropsychiatric disorders, particularly in the discovery and development of potential therapeutics. Their current research is focused on the pharmacology of psychedelics and their analogs, particularly for their potential role as neurotherapeutics.